Clinical Trial Detail

NCT ID NCT02398240
Title Brentuximab for Newly Diagnosed Hodgkin Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mitchell Cairo
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Doxorubicin + Rituximab + Vincristine Sulfate

Brentuximab vedotin + Doxorubicin + Vincristine Sulfate

Age Groups: child adult

No variant requirements are available.